Tresiba Mechanism of Action: The Full Pathway Explained

What Is Insulin Degludec and Why Its Structure Matters

Insulin degludec is a modified human insulin in which threonine at position B30 is deleted and a C16 fatty diacid chain (hexadecanedioic acid) is attached to lysine at B29 via a gamma-glutamic acid spacer. FDA labeling confirms this structural description. [1] Those two changes are responsible for every pharmacokinetic advantage the drug offers over older basal insulins.

The fatty acid chain is not decoration. It drives self-association into multi-hexamers and anchors the molecule to albumin in the bloodstream, extending its circulating half-life to roughly 25 hours. Published pharmacokinetic analyses confirm the ~25-hour half-life. [2]

Why the B30 Threonine Deletion Matters

Removing threonine at B30 reduces steric hindrance at the C-terminus of the B-chain. This allows adjacent hexamers to stack end-to-end in a linear arrangement that would be impossible in native human insulin. The result is a depot that behaves more like a slow-release polymer than a simple protein solution.

The Fatty Diacid Chain and Albumin Binding

Once monomers enter the capillary bed, the C16 fatty diacid binds reversibly to albumin. Albumin acts as a circulating buffer, releasing free monomer gradually. This dual mechanism, depot plus albumin binding, is described in detail in Jonassen et al., Pharm Res 2012. [2] No other approved basal insulin uses both mechanisms simultaneously.

Step 1: Subcutaneous Depot Formation

After subcutaneous injection, the pharmaceutical formulation contains phenol and zinc. Phenol stabilizes the T3R3 dihexamer conformation during storage. Once injected, phenol diffuses away rapidly. Without phenol, the zinc-stabilized hexamers rearrange and begin to associate end-to-end through fatty acid interactions, forming the multi-hexamer chains visible on electron microscopy. Structural characterization of the multi-hexamer depot is published in Havelund et al., Pharm Res 2004. [3]

Depot Kinetics

The multi-hexamer depot dissociates from its outer surface inward. Zinc diffuses out first, destabilizing surface hexamers into dihexamers, then hexamers, then dimers, and finally into the bioactive monomeric form. Each dissociation step takes time, and the cascade produces a remarkably flat absorption curve. Pharmacodynamic studies using euglycemic clamp show a coefficient of variation (CV) for the glucose infusion rate of approximately 20% for degludec vs. Approximately 82% for glargine U-100. [4]

A CV of 20% means the glucose-lowering effect on any given day is very close to the effect on every other day. That day-to-day consistency is the pharmacological basis for the lower hypoglycemia rates seen in clinical trials.

Time to Steady State

Because the half-life is approximately 25 hours, true pharmacokinetic steady state requires about 3 to 4 days (roughly 3 to 5 half-lives). Steady-state clamp data supporting this timeline appear in Heise et al., Diabetes Obes Metab 2012. [5] Clinicians adjusting the dose should wait at least 3 days between titration steps to avoid stacking effects.

Step 2: Albumin Binding in the Bloodstream

Free monomers that leave the depot enter capillaries and bind reversibly to serum albumin via the fatty diacid tail. Albumin binding prolongs the effective half-life by preventing rapid renal clearance. [2] Albumin-bound degludec is pharmacologically inactive; only the free monomer can bind the insulin receptor. The equilibrium between bound and free fractions is rapid (seconds to minutes) and concentration-dependent, so the system self-regulates to maintain a roughly constant free-monomer concentration throughout the dosing interval.

This contrasts with insulin glargine, which relies primarily on pH-dependent microprecipitation at the injection site and has no meaningful albumin-binding contribution to its prolonged action. The mechanistic differences between degludec and glargine are reviewed in Vora, Diabet Med 2013. [6]

Step 3: Insulin Receptor Binding and Activation

Receptor Isoform Selectivity

The insulin receptor exists as two isoforms: IR-A (exon 11 absent) and IR-B (exon 11 present). IR-A has higher affinity for IGF-1 and is expressed more heavily in fetal tissue and some cancers. IR-B predominates in adult liver, muscle, and adipose tissue and mediates the metabolic effects of insulin. IR isoform biology is reviewed thoroughly in Belfiore et al., Endocr Rev 2009. [7]

Degludec's in vitro receptor binding affinity is approximately 0.78 times that of native human insulin, and its IR-A/IR-B selectivity ratio is close to 1.0, essentially equivalent to human insulin. Receptor binding data for degludec are published in Kurtzhals et al., Diabetes 2000, as well as in the FDA pharmacology review. [8] This near-neutral isoform selectivity matters from a safety standpoint: preferential IR-A binding could theoretically promote mitogenic signaling, a concern that was raised with earlier insulin analogues.

IGF-1 Receptor Cross-Reactivity

Degludec's affinity for the IGF-1 receptor is approximately 0.11 times that of IGF-1 itself, lower than glargine's 0.81 times that of IGF-1. This comparison appears in the Kurtzhals et al. 2000 paper. [8] Lower IGF-1R affinity reduces the theoretical mitogenic risk, a point the FDA pharmacology reviewers noted favorably.

Post-Receptor Signaling Cascade

Once the degludec monomer occupies the insulin receptor's L1-CR-L2 binding site, the receptor undergoes conformational change and autophosphorylates tyrosine residues in the kinase domain (Tyr1158, Tyr1162, Tyr1163). The structural basis of insulin receptor activation is described in Ward et al., Acta Physiol 2019. [9] Activated IR then phosphorylates insulin receptor substrate proteins (IRS-1, IRS-2), which recruit PI3K, generate phosphatidylinositol-3,4,5-trisphosphate (PIP3), and activate Akt (also called PKB).

Akt phosphorylation drives three parallel downstream branches:

• GLUT4 translocation. Akt phosphorylates AS160 (TBC1D4), releasing GLUT4 vesicles to fuse with the plasma membrane in skeletal muscle and adipose tissue. GLUT4 translocation via the Akt-AS160 axis is reviewed in Sano et al., Mol Cell Biol 2003. [10]
• Glycogen synthesis. Akt inactivates glycogen synthase kinase-3 (GSK-3), allowing glycogen synthase to remain active and deposit glucose as hepatic and muscle glycogen. GSK-3 inhibition by Akt is described in Cross et al., Nature 1995. [11]
• Suppression of hepatic glucose output. Akt phosphorylates and excludes FOXO1 from the nucleus, reducing transcription of PEPCK and G6Pase, the two rate-limiting enzymes of gluconeogenesis and glycogenolysis. FOXO1 regulation of hepatic glucose production is reviewed in Barthel et al., Trends Endocrinol Metab 2003. [12]

Step 4: Hepatic Glucose Suppression, the Primary Basal Effect

During fasting, the liver produces approximately 8 to 10 grams of glucose per hour through gluconeogenesis and glycogenolysis. Basal hepatic glucose production rates in type 2 diabetes are quantified in Consoli et al., Diabetes 1989. [13] Basal insulin's principal job is to suppress this output overnight and between meals.

Degludec's flat pharmacodynamic profile means hepatic FOXO1 suppression is consistent across the 24-hour dosing interval. With glargine U-100, the absorption curve peaks at 4 to 6 hours post-injection; with degludec, euglycemic clamp studies show no discernible peak at all. The absence of a discernible peak in degludec's action curve is demonstrated in the Heise et al. 2012 clamp study. [5]

Clinical Translation: Fasting Plasma Glucose

The BEGIN trials (a series of phase 3 studies comparing degludec to glargine U-100) showed comparable reductions in HbA1c at 52 weeks. The BEGIN Once Long trial (N=1,030) is published in Zinman et al., Diabetes Care 2012. [14] The glucose-lowering efficacy is not superior to glargine, it is equivalent, but the flatter action profile changes the risk-benefit calculation for hypoglycemia.

Step 5: Mitogenic Signaling, How Degludec Compares

Insulin analogues activate not only the metabolic Akt branch but also the Ras-MAPK proliferative branch. The degree of MAPK activation relative to Akt activation determines the mitogenic-to-metabolic signal ratio. The mitogenic-to-metabolic ratio concept is formalized in Tennagels et al., Diabetologia 2008. [15]

Degludec's mitogenic-to-metabolic ratio in cell culture is approximately 1.0 times that of human insulin, meaning it does not preferentially drive proliferative signaling. This finding, combined with the low IGF-1R affinity noted above, supports the view that degludec carries no excess cancer signal beyond that of native insulin. Post-marketing safety surveillance data from the FDA support the absence of a new cancer signal. [1]

Step 6: Pharmacodynamic Consequences in Clinical Practice

Nocturnal Hypoglycemia Reduction

The DEVOTE trial (N=7,637, 2-year duration) compared degludec U-100 to glargine U-100 in adults with type 2 diabetes at high cardiovascular risk. Degludec produced a 27% reduction in severe hypoglycemia (rate ratio 0.73, 95% CI 0.60 to 0.89, P<0.001) and a 53% reduction in nocturnal severe hypoglycemia (rate ratio 0.47, 95% CI 0.31 to 0.73, P<0.001) compared with glargine U-100, while achieving non-inferior HbA1c reduction. DEVOTE is published in Marso et al., NEJM 2017. [16]

The mechanism behind this reduction is direct: the flat pharmacodynamic curve means insulin activity does not spike during the early morning hours (roughly 02:00 to 04:00) when cortisol is low and hypoglycemia counter-regulation is slowest.

Flexible Dosing and the Pharmacokinetic Margin

Because degludec's half-life is approximately 25 hours, changing the injection time by up to 8 hours on any given day does not meaningfully alter steady-state exposure. A dedicated flexible-dosing study (Mathieu et al., Diabetes Obes Metab 2013) confirmed non-inferior glycemic control when doses were given at intervals ranging from 8 to 40 hours. [17] This pharmacokinetic margin is clinically relevant for shift workers and patients with irregular schedules.

Dosing in Type 1 vs. Type 2 Diabetes

In type 1 diabetes, degludec is used alongside rapid-acting insulin at meals. The flat basal profile reduces the risk that the basal dose "leaks" into the post-meal period and compounds with bolus insulin to cause hypoglycemia. The BEGIN Basal-Bolus Type 1 trial (N=629) confirmed lower rates of nocturnal hypoglycemia with degludec vs. Glargine U-100 in type 1 diabetes. [18]

Comparing Degludec to Other Basal Insulins: Mechanistic Distinctions

The table below organizes the mechanistic differences across approved basal insulins. Each mechanism produces a distinct pharmacokinetic signature.

| Feature | Degludec U-100/U-200 | Glargine U-100 | Glargine U-300 | Detemir | |---|---|---|---|---| | Depot mechanism | Multi-hexamer chains | pH microprecipitate | pH microprecipitate (denser) | Dihexamers | | Albumin binding | Yes (C16 diacid) | No | No | Yes (C14 fatty acid) | | Half-life | ~25 hours | ~12 hours | ~19 hours | ~5 to 7 hours | | Duration | >42 hours | ~20 to 24 hours | ~36 hours | ~6 to 23 hours (dose-dependent) | | Day-to-day CV | ~20% | ~82% | ~43% | ~27% | | IGF-1R affinity vs. IGF-1 | ~0.11 | ~0.81 | ~0.81 | ~0.16 |

Data sources: Heise et al. 2012 [5], Kurtzhals et al. 2000 [8], FDA labeling [1].

Glargine U-300 achieves a longer duration than U-100 by forming a denser precipitate that takes longer to dissolve, a purely physical, not chemical, modification. Degludec's chemistry is categorically different: it solves the duration problem through molecular self-assembly and albumin binding rather than through concentration-dependent precipitation.

Pediatric Pharmacology

The FDA expanded degludec's label to children aged 1 year and older in 2019, based on the SCALE Kids trial. SCALE Kids pharmacokinetic data are summarized in the FDA label supplement. [19] The receptor signaling pathway is identical in pediatric patients, but the pharmacokinetic profile shows somewhat higher inter-individual variability. Weight-based dosing is used, and titration intervals remain at least 3 days.

Renal and Hepatic Considerations

Insulin is cleared by the liver (approximately 50% of portal insulin on first pass) and the kidney (the dominant route for peripheral insulin, including analogues). Insulin clearance physiology is reviewed in Duckworth et al., Pharmacol Rev 2018. [20] In advanced chronic kidney disease (eGFR <30 mL/min/1.73 m²), degludec clearance slows and hypoglycemia risk increases. The FDA label recommends more frequent glucose monitoring rather than a specific dose reduction formula. See current labeling for renal guidance. [1]

Hepatic impairment reduces first-pass insulin extraction, increasing bioavailability of peripherally injected degludec. Dose requirements may fall substantially in patients with Child-Pugh class B or C cirrhosis.

Cardiovascular Safety: What DEVOTE Tells Us Mechanistically

DEVOTE was a randomized, double-blind cardiovascular outcomes trial in 7,637 adults with type 2 diabetes and high cardiovascular risk, followed for a median of 2.0 years. The primary endpoint was a three-component MACE (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke). Degludec was non-inferior to glargine U-100 for MACE (HR 0.91, 95% CI 0.78 to 1.06). [16]

The cardiovascular non-inferiority finding is mechanistically reassuring for two reasons. First, degludec's near-neutral IGF-1R affinity means it does not activate the proliferative pathways that could accelerate atherosclerosis. Second, the reduction in severe hypoglycemia likely reduces hypoglycemia-driven catecholamine surges, which are a recognized trigger for arrhythmia and acute coronary events. The link between hypoglycemia, catecholamine release, and cardiac events is reviewed in Frier et al., Lancet Diabetes Endocrinol 2014. [21]

Dr. Steven Marso, principal investigator of DEVOTE, stated in the published report: "Among patients with type 2 diabetes at high risk for cardiovascular events, the rates of serious adverse events were similar between the insulin degludec and insulin glargine groups." [16] The 27% reduction in overall severe hypoglycemia was a pre-specified secondary endpoint and reached statistical significance (P<0.001).

Practical Dosing Informed by the Mechanism

The ADA Standards of Medical Care in Diabetes (2024 edition) list degludec as a preferred basal insulin option when hypoglycemia is a primary concern, particularly in older adults or those with hypoglycemia unawareness. ADA Standards of Medical Care 2024 are available at Diabetes Care. [22]

Starting dose guidance derived from the pharmacokinetic profile:

• Insulin-naive type 2 diabetes: 10 units once daily, titrated by 2 units every 3 days to a fasting glucose target of 80 to 130 mg/dL.
• Switching from glargine U-100 or detemir: 1-to-1 unit conversion, then titrate.
• Switching from NPH: reduce the total daily dose by 20% at initiation (due to degludec's stronger and more consistent suppression of fasting glucose), then titrate upward if needed.

The 3-day titration interval is mechanistically mandated: with a 25-hour half-life, steady state is not reached until approximately day 3 to 4, so adjusting the dose sooner risks stacking. This recommendation is consistent with Heise et al. 2012 steady-state clamp data. [5]